Australia: The plausibility threshold for patent specifications remains low in Australia

The requirement that a patent specification sufficiently enables the subject matter of the claims is particularly relevant to pharmaceutical inventions and can be a hurdle for innovators even if a claimed invention is deemed novel and inventive. In the absence of any prior art, the claimed invention can fail the enablement requirement if it is not plausible at the date of filing that the invention would work across the full scope of the claims in the eyes of a person skilled in the art. As reported previously, the majority of the UK Supreme Court disagreed with the principle that plausibility is a "low, threshold test" and required that the patent specification itself provides a reasonable basis for the scope of the claims. However, a recent decision of the Patent Office in Gary B Cox v MacroGenics, Inc. [2019] APO 13 (MacroGenics) suggests that plausibility is still a low threshold in Australia, and that the common general knowledge can be drawn upon to enable the claims.

The Invention

Australian Patent Application No. 2012259162 owned by MacroGenics, Inc. relates to a protein-based therapeutic with extended serum half-life. More specifically, it is directed to a polypeptide comprising a portion of a de-immunized albumin-binding protein capable of binding to serum albumin. The de-immunized albumin-binding protein is a variant of a wild-type albumin-binding domain (ABD) of Streptococcal Protein G. The application disclosed that specific mutations of the ABDs not only extended serum half-life but also decreased immunogenicity relative to the unmodified proteins. Such protein properties are likely to maximize therapeutic efficacy without triggering a heightened immune response.

Plausibility and Undue Burden

In considering the requirement of "plausibility" under section 40(2)(a) as amended by the Raising the Bar Act 2012, the Delegate noted the absence of Federal Court authority on this provision, and cited the approach from an earlier Patent Office decision Evolva SA [2017] APO 57 ( Evolva) which stated that enablement of a claim should be determined according to a 2-step test (emphasis added):

Does the specification provide an enabling disclosure of all the things that fall within the scope of the claims, and in particular:

  1. Is it plausible that the invention can be worked across the full scope of the claim?
  2. Can the invention be performed across the full scope of the claim without undue burden?

In Evolva, the Deputy Commissioner stated that the threshold for plausibility is a low one, and may be based on the slimmest of evidence, citing Human Genome Sciences Inc v Eli Lilly & Co [2011] UKSC 51 in which Lord Neuberger indicated that in some cases a "plausible" or "reasonably credible" claimed use, or an "educated guess", can suffice.

The Delegate in MacroGenics also cited Warner-Lambert v Generics & Anr [2018] UKSC 56 (Warner-Lambert), a recent UK Supreme Court judgement, regarding the plausibility aspect of enablement. In Warner-Lambert the majority of the Supreme Court found that plausibility should be derived from the disclosure of the specification read through the eyes of the skilled person in light of their common general knowledge. Although the disclosure need not definitively prove the assertion that the product works for the designated purpose, there must be something that would cause the skilled person to think that there was a reasonable prospect that the assertion would prove to be true. In contrast, the minority of the Supreme Court thought such a standard for plausibility was too high and that the patentee should not have to demonstrate within its patent a prima facie case of efficacy.

While the Delegate observed "it is clear that the Supreme Court has adopted a higher threshold with respect to plausibility..." (emphasis added) the Delegate did not see this as inconsistent with the decision in Evolva. The Delegate stated "It remains the case that, as set out in Evolva, the consideration is one of technical credibility or believability. Plausibility may be a low threshold, but it is a threshold nonetheless, and is not satisfied by mere speculation or assertion".

With regard to "undue burden" the Delegate referenced the following statements from Evolva and Eli Lilly & Co v Human Genome Sciences, Inc. [2008] EWHC 1903 respectively:

"My understanding of these authorities is that the emphasis in relation to undue burden has been on the nature of the work that is required by the skilled person in view of the guidance in the specification. To this end, one approach has been to ask whether the skilled person would be required to undertake a 'research programme' in order to perform the invention."
"... patent specifications need not set out every detail necessary for performance, but can leave the skilled man to use his skill to perform the invention. In so doing he must seek success. He should not be required to carry out any prolonged research, enquiry or experiment. He may need to carry out the ordinary methods of trial and error, which involve no inventive step and generally are necessary in applying the particular discovery to produce a practical result. In each case, it is a question of fact, depending on the nature of the invention, as to whether the steps needed to perform the invention are ordinary steps of trial and error which a skilled man would realise would be necessary and normal to produce a practical result."

In MacroGenics, lack of enablement was asserted in two ways. Firstly, that the conjugation of the ABD to any polypeptide was not enabled as the specification was largely directed to diabodies; and secondly that the claims were not enabled with regard to variants of the specific ABDs exemplified. With regard to the first of these, the Delegate found it plausible that fusion of a deimmunised ABD as defined in the claims to any polypeptide would extend the serum half-life of that polypeptide and that there was no undue burden on the skilled person in working the invention in this respect. As to the second issue, the Delegate found that ABD variants satisfying the functional requirements of the claim could be identified and used to extend polypeptide half-life. However, the Delegate considered that, given the large number of possible mutations to ABD, identification of variants with the desired properties would be unpredictable in light of the limited guidance provided in the specification. While such work would be routine, the Delegate was of the opinion that it would be an undue burden to work the invention across the full scope of the claims. The specification was thus found to lack enablement under section 40(2)(a).

The findings of the Delegate provides confirmation that the standard for "plausibility" is low in Australia. To satisfy this standard, the patent was not required to demonstrate a prima facie case that fusion of the claimed ABD to any polypeptide would extend serum half-life or that the ABD variants claimed are deimmunized and could be used to extend polypeptide half-life. The Delegate stated that plausibility is a low threshold not requiring definitive proof and the Delegate appeared to notably rely on evidence of the common general knowledge rather than drawing from the disclosure in the patent specification itself. Nevertheless, due to the unpredictable nature of this technology, it was deemed an "undue burden" to perform the invention particularly because the specification provided no indication on what is and is not likely to work or guidance on how to proceed when confronted with failures.

The Delegate further noted that the present circumstances were quite different from the one contemplated in Evolva, where the claimed polypeptide was limited by sequence homology and by structure-function. MacroGenics, Inc. has been given two months from the date of the decision to amend the claims to overcome the findings of the Delegate and have filed amendments to limit the claimed ABD variant by sequence homology.


Biotechnology and pharmaceuticals are areas of technology often struck by unpredictability. While the assessment of enablement will continue to be a case-by-case approach, the Evolva and MacroGenics decisions provide some guidance on how the Australian Patent Office is likely to assess plausibility.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Shelston IP ranked one of Australia's leading Intellectual Property firms in 2015.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions